Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
624 Views
eMediNexus 27 July 2021
Individuals who had an allergic reaction to a first dose of the Pfizer/BioNTech or Moderna mRNA COVID-19 vaccine tolerated a second dose safely, reported a retrospective, multicenter study.
Overall, 17% of the 189 individuals with initial allergic reactions had anaphylaxis. Other reactions to the first dose included erythema, dizziness, tingling, throat tightness, hives, and wheezing or shortness of breath. Among the 189 people with initial allergic reactions, researchers assessed 159 (84%) who took the second dose. All the individuals, including 19 people with first-dose anaphylaxis, tolerated the second dose. Thirty two people who took a second dose developed immediate and potentially allergic symptoms. About 20% of the individuals had symptoms with the second dose, but they were manageable and not anaphylactic, noted researchers. The findings are published in JAMA Internal Medicine… (Medscape)
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Kerala Doctors Achieve World-First In Treating Dual Brain Infections..
GST Council Cuts Tax On Medicines, Devices To Boost Affordable Healthcare..
Protest Erupts at Ramanathapuram Medical College Hospital Over Alleged Medical Negligence..
Panel Rejects Proposal to Add Nine Conditions Under RPWD Act Disability List..
Overdose Deaths Rise Among Older Australians, Report Warns..
eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.
